Your privacy is very important to us.When you visit our website,please agree to the use of all cookies.For more information about personal data processing,please go t0 《Privacy Policy Statement》

中
En
About Us
Overview
Founder
Platform
Milestones
Culture
Honors
Core Technology
Technological platforms
Pipeline
Academic achievements
Clinical Trials
News
Company News
Join Us
Social Recruitment
Campus Recruitment
Contact
xinwen.jpg pcxinwendongtai.jpg

News
Company News
4haolouwailimiandailogo.jpg
No lymphodepletion or IL-2 injection required, GC101 TIL demonstrates good safety and objective efficacy in Phase I clinical study!

2023.04.08
Learen More +
dianfuxing.jpg
Juncell Therapeutics wins the highest award in the National Disruptive Technology Innovation Competition sponsored by the Ministry of Science and Technology

2023.02.28
Learen More +
liebiaotu-961.jpg
Juncell Therapeutics is granted implied IND approval by NMPA for its first TIL therapy

2022.04.24
Learen More +
3.jpg
Raising ¥ 150 million in A+ and A++ rounds, Juncell Therapeutics will accelerate the progress of TIL therapy pipelines!

2022.01.15
Learen More +
3-260.jpg
Juncell Therapeutics completes series A Financing round at a level of nearly ¥ 100 million to accelerate new TIL pipeline advancement

2021.02.26
Learen More +